Brunel Laboratoria expands pharmaceutical portfolio with acquisition of MYOPRIN 100 mg tablets

Centurion, South Africa – 1 July 2025 – Brunel Laboratoria (Pty) Ltd is pleased to announce the successful acquisition of MYOPRIN 100 mg Tablets 30’s from iPharma (Pty) Ltd, marking another strategic milestone in Brunel’s continued expansion within the South African pharmaceutical sector.

This acquisition underscores Brunel’s commitment to advancing healthcare by expanding its portfolio with clinically proven, high-quality medicines that meet the evolving needs of patients and healthcare professionals alike.

“The addition of MYOPRIN to our portfolio strengthens our offering in cardiovascular support and underscores Brunel’s commitment to delivering clinically trusted, cost-effective medicines. We understand the critical role healthcare professionals and supply partners play in patient care, and we are dedicated to ensuring uninterrupted access, consistent quality, and responsive service across every touchpoint.”

— Michiel Venter, CEO, Brunel Laboratoria (Pty) Ltd

From 1 July 2025, customers may place orders directly through their Brunel sales representative or contact Brunel Head Office at (012) 666 8994 or info@brunel.co.za.

Brunel remains steadfast in upholding the highest standards of quality, compliance, and customer-centric service. This acquisition reflects the company’s broader vision to be a trusted partner in healthcare delivery — for professionals, patients, and the industry alike.

Media contact

Brunel Laboratoria (Pty) Ltd
Email: info@brunel.co.za
Tel: (012) 666 8994
Website: www.brunel.co.za

Back to blog posts on living well with Brunel